American Association for Cancer Research
crc-23-0221_fig4.png (3.22 MB)

FIGURE 4 from The Oncolytic Activity of Zika Viral Therapy in Human Neuroblastoma In Vivo Models Confers a Major Survival Advantage in a CD24-dependent Manner

Download (3.22 MB)
posted on 2024-01-09, 14:20 authored by Joseph Mazar, Jeanne K. Brooks, Matthew Peloquin, Rosa Rosario, Emma Sutton, Matthew Longo, Dennis Drehner, Tamarah J. Westmoreland

Evaluation of the Zika viral time course on neuroblastoma tumors by IHC. ZIKV-treated tumors were compared with vehicle-treated tumors at each timepoint. A, IMR-32 tumors were H&E stained at day 0, 2, 5, and 7 posttreatment. Percent necrosis is indicated under each image. B, IMR-32 tumors were stained using a Zika viral NS1 protein antibody at day 0, 2, 5, and 7 posttreatment. C, SK-N-AS tumors were H&E stained at day 0, 4, 7, and 10 posttreatment. Percent necrosis is indicated under each image. D, SK-N-AS tumors were stained using a Zika viral NS1 protein antibody at day 0, 4, 7, and 10 posttreatment. Tissues were stained using a Leica Bond Maxfive and images were generated using an Olympus BX43 at 40x magnification with a 10x zoom.


Nemours Children's Hospital



Neuroblastoma is the most common extracranial tumor, accounting for 15% of all childhood cancer-related deaths. The long-term survival of patients with high-risk tumors is less than 40%, and MYCN amplification is one of the most common indicators of poor outcomes. Zika virus (ZIKV) is a mosquito-borne flavivirus associated with mild constitutional symptoms outside the fetal period. Our published data showed that high-risk and recurrent neuroblastoma cells are permissive to ZIKV infection, resulting in cell type–specific lysis. In this study, we assessed the efficacy of ZIKV as an oncolytic treatment for high-risk neuroblastoma using in vivo tumor models. Utilizing both MYCN-amplified and non-amplified models, we demonstrated that the application of ZIKV had a rapid tumoricidal effect. This led to a nearly total loss of the tumor mass without evidence of recurrence, offering a robust survival advantage to the host. Detection of the viral NS1 protein within the tumors confirmed that a permissive infection preceded tissue necrosis. Despite robust titers within the tumor, viral shedding to the host was poor and diminished rapidly, correlating with no detectable side effects to the murine host. Assessments from both primary pretreatment and recurrent posttreatment isolates confirmed that permissive sensitivity to ZIKV killing was dependent on the expression of CD24, which was highly expressed in neuroblastomas and conferred a proliferative advantage to tumor growth. Exploiting this viral sensitivity to CD24 offers the possibility of its use as a prognostic target for a broad population of expressing cancers, many of which have shown resistance to current clinical therapies. Sensitivity to the tumoricidal effect of ZIKV on high-risk neuroblastoma tumors is dependent on CD24 expression, offering a prognostic marker for this oncolytic therapy in an extensive array of CD24-expressing cancers.

Usage metrics

    Cancer Research Communications



    Ref. manager